Basal cell carcinoma - metastatic or locally advanced

The PBS subsidises sonidegib and vismodegib for patients with metastatic or locally advanced basal cell carcinoma (BCC).

You’ll get an immediate assessment when you request PBS authorities online.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with sonidegib and vismodegib under the National Health Act 1953, section 85 for adult patients with metastatic or locally advanced basal cell carcinoma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing sonidegib and vismodegib.

Authority applications

Applying for initial treatment

Applications for initial authority approval to prescribe PBS-subsidised sonidegib or vismodegib to treat metastatic or locally advanced BCC can be made either in:

All written applications must include the completed:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised sonidegib or vismodegib to treat metastatic or locally advanced BCC can be made either in:

All written applications must include the completed:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 26 September 2022